Cosmo Bio Co

Cosmo Bio Co Accounts Payable

The Accounts Payable of Cosmo Bio Co (3386.T) as of Oct 27, 2026 is 806.00 M JPY. In the previous year, Accounts Payable was 747.00 M JPY — a change of 7.90% (higher).

Accounts Payable

806.00 MJPY

YoY

7.90%

Last updated:

Accounts Payable of Cosmo Bio Co is 2025 806.00 M JPY. Accounts Payable of Cosmo Bio Co was 2024 747.00 M JPY. It decreases by 7.90% higher compared to the previous year.

The Cosmo Bio Co Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2018
540.00 M JPY
Jan 1, 2019
565.00 M JPY
Jan 1, 2020
488.00 M JPY
Jan 1, 2021
592.00 M JPY
Jan 1, 2022
573.00 M JPY
Jan 1, 2023
639.00 M JPY
Jan 1, 2024
747.00 M JPY
Jan 1, 2025
806.00 M JPY
The Cosmo Bio Co Accounts Payable history
YEARAccounts PayableYoY
806.00 MJPY+7.90%
747.00 MJPY+16.90%
639.00 MJPY+11.52%
573.00 MJPY-3.21%
592.00 MJPY+21.31%
488.00 MJPY-13.63%
565.00 MJPY+4.63%
540.00 MJPY+4.65%
516.00 MJPY+11.69%
462.00 MJPY-20.75%
583.00 MJPY-15.38%
689.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

Accounts Payable of Cosmo Bio Co is 806.00 M JPY in 2025.

Accounts Payable of Cosmo Bio Co changed from 747.00 M JPY to 806.00 M JPY, representing a 7.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Cosmo Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co